Africa Live News

Visa and Jason Sudeikis Turn the Simplest Goal in Football Into the Biggest Fan Moments at the FIFA World Cup 2026™

africa-live — Tue, 19 May 2026 07:53:19 GMT

SAN FRANCISCO - Monday, 18. May 2026 AETOSWire

With “Tap In,” Visa brings fans closer to the FIFA World Cup 2026™—one effortless tap at a time.

(BUSINESS WIRE) -- At the FIFA World Cup 2026™, everything can change in a split second. A quick pass. A simple finish. A tap in goal. This summer, Visa (NYSE: V), the Worldwide Payment Technology Partner of the FIFA World Cup 2026™, is turning those fleeting moments into something much bigger—launching Tap In, a bold new global campaign based on the belief that everything is a tap in with Visa.

Built around one of football’s most recognizable finishes, Tap In takes the simplest touch in the game and turns it into a powerful metaphor for how Visa works: fast, seamless, and effortless in the moments that matter most. At the FIFA World Cup™, that idea moves beyond storytelling, unlocking opportunity in communities and connecting fans directly to the action as it unfolds live.

When Players Tap In, Fans Do Too

At the heart of the campaign, Visa brings the passion of football to life across all three host countries—delivering exclusive promotions, unforgettable moments, and once-in-a-lifetime prizes to cardholders. When the ball hits the back of the net, the moment doesn’t stop at the stadium—it travels instantly to fans’ screens.

Visa cardholders across the United States and Canada can register to enter Tap In to Score1, a Visa exclusive promotion that can make every match and every tap in goal mean something more. Fans can stay connected throughout the tournament for a chance to win daily, knowing the next tap in goal on the pitch could unlock even more prizes. From FIFA World Cup™ match tickets and a potential trip to the Final, to signed memorabilia and limited-edition merchandise, Tap In to Score turns match moments into shared celebration and opportunity.

With a simple, repeatable cadence that mirrors the flow of the tournament, Tap In to Score is designed to keep fans engaged beyond kickoff—making participation easy, intuitive, and woven into the rhythm of every matchday.

In Mexico, eligible Visa cardholders can register to enter Pásala Para Ganar2—a promotion offering fans the chance to win tickets to a FIFA World Cup 2026™ match just by registering their eligible cards. Winners will be randomly selected and notified in early June.

Jason Sudeikis Leads a Global Roster Built for the Moment

To bring Tap In to life, Visa has assembled a lineup that blends humor, cultural credibility, and football greatness. The campaign launches with a high impact hero film that captures the unpredictability, energy, and joy of the FIFA World Cup™—showing how a single tap can ripple far beyond the pitch.

Award winning actor Jason Sudeikis anchors the campaign, journeying through the U.S., Mexico and Canada, using his Visa card to make every step of his FIFA World Cup 2026™ experience easier—illustrating how Visa removes friction and unlocks fandom in real life.

He is joined in the Tap In campaign by some of the most exciting and iconic figures in the tournament today, including Lamine Yamal, Erling Haaland, Christian Pulisic, Jorge Campos, and legendary announcer, Andrés Cantor.

Together, they celebrate a simple truth fans instantly recognize: the smallest touches can create the biggest moments.

“Football has this way of making even the smallest moment feel shared,” said Jason Sudeikis. “Tap In helps fans stay connected to that feeling—whether they’re on the pitch, in the stands, or at home.”

From Screens to Streets: Making the FIFA World Cup™ a Connected Experience

Tap In rolls out across broadcast, digital, social, creator partnerships, and live fan moments—meeting fans where football culture lives today. Tap In notifications, creator-led explainers, and immersive environments bring Tap In to life as an always-on FIFA World Cup™ experience.

Visa’s Tap In Studio activation at select stadiums and major host cities invites fans to step inside the campaign, blending football, art—from Visa’s first-ever global art collection—and culture, while unlocking an experience only Visa can deliver.

Tap In to Impact

Visa’s Tap In campaign is also taking the energy of the FIFA World Cup™ and turning it into economic impact that directly supports small businesses, creators and communities across host countries.

Through Tap In to Impact, Visa is committing $600,000 to three nonprofit partners across each host country: SCORE in the United States, Pro Mujer in Mexico, and Futurpreneur in Canada. These investments support the local business owners, mentors, and community-builders transforming a global tournament into lasting local impact, ensuring the excitement of the FIFA World Cup™ leaves a lasting legacy where it’s played.

Everything Is a Tap In With Visa

“Fans don’t just watch the FIFA World Cup™—they live it,” said Frank Cooper III, Chief Marketing Officer at Visa. “Tap In keeps them closer to every moment, turning the easiest goal in football into an invitation for fans everywhere to participate. One tap, and you’re in.”

To learn more about Visa’s Tap In to Score and how to register to enter for a chance to win match-triggered prizes, visit visa.com and follow Visa on social.

About Visa

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, sellers, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

1 NO PURCHASE NECESSARY. Must be current Visa cardholder as of May 1, 2026, 50 U.S./D.C., PR, or CAN, 18+/age of maj. Match Ticket winners responsible for travel & accommodations. For CAN res. Skill test req’d. Ends July 20, 2026. Rules/Elig: https://tevnt.com/VisaFWC26Promo

2 Rules/Elig: https://tevnt.com/VisaFWC26Promo/mx/

View source version on businesswire.com: https://www.businesswire.com/news/home/20260518011231/en/

Permalink
https://www.aetoswire.com/en/news/1805202655123

Contacts
Media Contact
Conor Febos, cfebos@visa.com

STARTEEPO Invest Announces 5% Stake in Xerox Holdings Corporation

africa-live — Mon, 18 May 2026 06:40:26 GMT

PRAGUE - Saturday, 16. May 2026 (BUSINESS WIRE)--STARTEEPO Invest (“STARTEEPO”), an alternative investment fund focused on public equity opportunities, today announced that it has acquired a significant ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515594020/en/ As of the date of this release, STARTEEPO and its affiliates beneficially owns 6.6 million shares of Xerox (excluding options), representing approximately 5.05% of the Company’s outstanding common stock. STARTEEPO has filed a Schedule 13D with the U.S. Securities and Exchange Commission (the “SEC”) providing additional details regarding its investment. Investment Perspective STARTEEPO believes that Xerox represents an interesting investment opportunity supported by a combination of balance sheet initiatives, ongoing operational improvements, and its position within a changing and consolidating industry. In STARTEEPO’s view, the Company is undergoing a multi-step transition focused on stabilizing revenues, improving margins, and strengthening its financial profile over time. STARTEEPO believes that even incremental progress across these areas may contribute to a more balanced market perception. Shareholder Approach STARTEEPO intends to act as a constructive, long-term shareholder and may engage in discussions with Xerox’s management and Board of Directors regarding the Company’s business, strategy, capital structure, and opportunities to enhance shareholder value. The firm may also communicate its investment perspective to institutional investors and market participants. František Bostl, Chairman of the Board of STARTEEPO Invest, commented: “We view Xerox as a deep value opportunity and today it represents one of the largest positions in our portfolio, reflecting our strong conviction in the company’s long-term potential. We are honored to become part of the history of this iconic technology company.” Additional information are available at www.starteepo.com/xerox. About STARTEEPO Invest STARTEEPO Invest is an alternative investment fund based in Prague, Czech Republic, focused on identifying high-conviction opportunities in public equity markets. The firm applies a fundamental, long-term investment approach, with a focus on disciplined analysis and constructive engagement. This communication expresses solely the opinion of STARTEEPO and its affiliates and not any other party. This communication is for informational purposes only and does not constitute investment advice, a recommendation, or offer to buy or sell any securities. STARTEEPO’s opinions stated herein are based on publicly available information and its own analyses. STARTEEPO may, at any time and without notice, buy, sell, reduce, increase, or otherwise change its investment position, including for reasons that may be inconsistent with the views expressed in this communication. Investing in securities involves significant risks, including the potential loss of the principal amount invested. Past performance is not a reliable indicator of future results. Every investor should conduct their own independent research and due diligence or consult with a licensed financial, legal, or tax advisor before making any investment decision. View source version on businesswire.com: https://www.businesswire.com/news/home/20260515594020/en/ Permalink https://www.aetoswire.com/en/news/1605202655103 Contacts Media Contact Frantisek Bostl bostl@starteepo.com 420 604 215 002 www.starteepo.com/en

TetraMem Announces 22nm Multi-Level RRAM Analog In-Memory Computing SoC Milestone

africa-live — Mon, 18 May 2026 05:37:51 GMT

(BUSINESS WIRE)--TetraMem Inc., a Silicon Valley–based semiconductor company developing analog in-memory computing (IMC) solutions, today announced the successful tape-out, manufacturing, and initial silicon validation of its MLX200 platform, a 22nm multi-level RRAM-based analog IMC system-on-chip (SoC).

The achievement marks a significant step toward the commercialization of analog computing architectures based on emerging non-volatile memory technologies, addressing the growing challenges of data movement, power consumption, and thermal constraints in modern AI systems.

As AI workloads continue to scale, system performance is increasingly constrained by the cost of moving data between memory and compute units. Analog in-memory computing offers a fundamentally different approach by performing computation directly within memory arrays, significantly reducing data movement and improving system-level efficiency. TetraMem’s MLX200 platform integrates multi-level RRAM arrays with mixed-signal compute engines to enable high-throughput vector-matrix operations within memory, while maintaining compatibility with advanced CMOS processes.

The multi-level RRAM technology demonstrated at the TSMC 22nm process provides key attributes required for practical deployment, including CMOS compatibility with minimal additional process complexity, low-voltage and low-current operation, strong retention and endurance characteristics, and high multi-level capability that supports improved memory and compute density. Early silicon results indicate consistent functionality across arrays, supporting the viability of this approach for both embedded non-volatile memory and compute-in-memory applications.

This milestone builds on TetraMem’s earlier work on the MX100 platform, fabricated on the TSMC 65nm CMOS process, where the company demonstrated multi-level RRAM devices with thousands of conductance levels (“Thousands of conductance levels in memristors integrated on CMOS,” Nature, March 2023), as well as high-precision analog computing capabilities (“Programming memristor arrays with arbitrarily high precision for analog computing,” Science, February 2024). These prior results established a strong scientific and engineering foundation for scaling the technology to more advanced nodes.

Since 2019, TetraMem has worked closely with the world leading semiconductor foundry to advance RRAM technology from early-stage research into manufacturable silicon. The progress achieved at 22nm reflects continued development in process integration, device uniformity, and system-level co-design.

The MLX200 and MLX201 platforms are designed to support power- and latency-sensitive edge AI applications, including voice and audio processing, wearable devices, IoT systems, and always-on sensing. Evaluated sampling is expected to begin in the second half of 2026, and multi-level RRAM memory IP is available for evaluation and potential licensing.

Dr. Glenn Ge, Co-founder and CEO of TetraMem, commented, “This milestone reflects years of close collaboration with our foundry partner TSMC and demonstrates the feasibility of bringing multi-level RRAM and analog in-memory computing from computing architecture breakthrough into advanced-node commercial silicon. We believe this approach provides a practical path to improving energy efficiency and scalability for next-generation AI systems.”

The successful realization of the MLX200 platform highlights the viability of multi-level RRAM-based analog computing on advanced semiconductor processes. TetraMem will continue to advance this technology to support emerging AI workloads with improved energy efficiency and system scalability.

About TetraMem

TetraMem is a Silicon Valley–based semiconductor company pioneering analog in-memory computing using multi-level RRAM technology. Its architecture integrates memory and compute to significantly reduce data movement and improve energy efficiency for AI workloads. With a strong foundation in device, circuit, and system co-design, TetraMem is advancing scalable solutions for edge AI and future high-performance computing, working closely with leading foundries and ecosystem partners to bring fundamental science breakthrough technologies into commercial variable volume production.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260516556464/en/

Permalink
https://aetoswire.com/en/news/1605202655113

Contacts
Media Contact:
Glenn Ge
pr@tetramem.com

n

Modon partners with Montage Hotels & Resorts to bring ultra-luxury hospitality brand to Egypt’s Ras El Hekma

africanewsline — Mon, 18 May 2026 05:28:20 GMT

Ras El Hekma, Egypt - Sunday, 17. May 2026 AETOSWire Print Montage Ras El Hekma introduces the first branded residences for purchase at the Mediterranean destination, alongside the region’s first Montage resort Abu Dhabi-based Modon Holding and Montage Hotels & Resorts have announced Montage Ras El Hekma, which will introduce the first branded residences for purchase at Ras El Hekma on Egypt’s Mediterranean coast. This is the first Montage resort in Egypt – supporting the emerging city’s growth as a global hub for leisure, business and tourism. Montage Ras El Hekma will feature 200 guestrooms and suites, in addition to 96 Montage Residences, and will offer a curated mix of wellness and leisure amenities, including beachfront swimmable lagoons, a Spa Montage with 13 treatment rooms, and six dining venues, alongside retail and family-oriented experiences. Designed as the experiential core of the wider community, the resort will also feature event spaces, expansive outdoor lawns and terraces, and a dedicated Owners’ Clubhouse that complements the private residential setting. At the heart of the Ras El Hekma development, the resort will create a hospitality-led living environment, blending private ownership with Montage’s signature approach to intuitive, understated luxury and a fully serviced lifestyle defined by ease, privacy and discretion. With no future phases planned for this collection, the residences represent a rare and highly exclusive ownership opportunity within a layered coastal setting that brings together 2.25 kilometres of shoreline, rolling fairways, an integrated marina and world-class hospitality experiences. Bill O’Regan, Group CEO of Modon Holding, said: “Montage Hotels & Resorts are renowned for serving affluent travellers and homeowners, delivering an elevated guest experience and a commitment to refined living while remaining authentic to their surroundings. This ethos aligns closely with Modon’s vision for Ras El Hekma, where we are creating a distinctive Mediterranean destination defined by quality, experience and long-term value.” Montage Residences Ras El Hekma comprise of a private collection of 96 branded villas positioned in Wadi Yemm, Ras El Hekma’s first precinct, designed to maximise space, light, privacy and seamless indoor-outdoor living. The three- to six-bedroom villas are oriented towards the sea, reinforcing a strong connection to the surrounding land and natural environment, with select homes offering dual views across the Mediterranean and a championship golf course. Montage Ras El Hekma marks the international ultra-luxury brand’s debut in the country and the start of a broader partnership between Modon and Montage, with potential for further collaboration across Modon’s destinations. New properties will add to Montage Hotels & Resorts’ existing portfolio of six ultra-luxury resorts and residences across the United States and Mexico, as well as additional properties planned in the Bahamas, Punta Mita, and Valle de Guadalupe. Alan J. Fuerstman, Founder, Chairman and CEO of Montage International, said: “Bringing the Montage brand to Egypt with Modon is a truly exciting milestone in our global journey. Ras El Hekma is a remarkable destination, where rich heritage and thoughtful design come together in a way that is redefining luxury along the Mediterranean coast. We are honoured to collaborate with Modon to bring this vision to life and to build on their outstanding reputation for creating vibrant communities and delivering world-class sporting and lifestyle experiences.” Montage Ras El Hekma forms part of the USD 35 billion Ras El Hekma masterplan, a 170.8 million square metre development transforming Egypt’s Northern Coast into a next-generation city expected to attract investment of USD 110 billion by 2045. The resort and residences will be set within Wadi Yemm, the first of Ras El Hekma’s 17 planned precincts to move into active delivery. As the city’s first fully integrated coastal community, it represents the opening chapter of the broader masterplan vision. Wadi Yemm will also feature a series of cultural landmarks that will help shape the identity of the wider city, including the Ras El Hekma Lighthouse and an amphitheatre designed to host up to 10,000 guests across an annual programme of cultural and entertainment events. Ras El Hekma is designed for seamless access by road, sea, and air, placing it within four hours’ flight time of nearly half the world’s population. The destination will include a new international airport integrated with high-speed rail networks, major highways, and marinas, alongside a dedicated cruise terminal. Spanning 44 kilometres of Mediterranean coastline, Ras El Hekma will deliver a mix of leisure, hospitality and cultural offerings. At its core, the destination will feature a central business and financial district, supported by education, residential and mixed-use districts designed to sustain a vibrant year-round community. Upon completion, Ras El Hekma is expected to contribute approximately USD 25 billion annually to Egypt’s GDP and create around 750,000 jobs, establishing it as one of the region’s largest urban development and investment projects. For more information, prospective buyers can visit modon.com or call 800 MODON in the UAE, 7734 in Egypt, or +201122222734 for international enquiries. For more information on Montage Ras El Hekma, please visit www.montage.com and follow @montagehotels and @montageraselhekma. About Modon Modon is an international holding company, headquartered in Abu Dhabi, United Arab Emirates, and listed on the Abu Dhabi Securities Exchange (ADX). Modon is at the forefront of urban innovation, creating iconic designs and experiences that continually surpass expectations. From real estate to hospitality, asset and investment management, events, catering and tourism, and urban infrastructure, we are bringing cities to life through delivering long-term and sustainable value. About Montage Hotels & Resorts Montage Hotels & Resorts is the ultra-luxury hospitality management company founded by Alan J. Fuerstman. Designed to serve the affluent and discerning traveler and homeowner, the company features an artistic collection of distinctive hotels, resorts, and residences. Each Montage property offers comfortable elegance, a unique sense of place and spirit, impeccable hospitality and memorable culinary, spa and lifestyle experiences. The portfolio of hotels, resorts and residences includes: Montage Laguna Beach, Montage Deer Valley, Montage Palmetto Bluff, Montage Los Cabos, Montage Healdsburg, and Montage Big Sky. Future destinations include Montage Cay, Montage Punta Mita, Montage Valle de Guadalupe and Montage Ras El Hekma. Montage Hotels & Resorts is a member of Preferred Hotels & Resorts. For more information, follow @montagehotels or visit www.montage.com. Permalink https://www.aetoswire.com/en/news/1705202655114 Contacts For further information, please contact press@modon.com, visit www.modon.com or follow LinkedIn X Instagram Facebook YouTube

Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI

africanewsline — Sat, 16 May 2026 06:22:53 GMT

LONDON - Friday, 15. May 2026 AETOSWire Print New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations (BUSINESS WIRE)--Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership enables agentic AI to scale well beyond pilot deployments. With the Experian Ascend Platform natively connected to the ServiceNow AI Platform, AI agents can seamlessly access Experian’s trusted insights and decisioning capabilities directly within existing workflows, giving clients the unique opportunity to automate intelligence at scale. Keith Little, President - Experian Software Solutions, said: “We see agentic AI as a fundamental change in how intelligent services are delivered, and this partnership brings together complementary strengths and a shared vision for building them the right way. “By connecting our intelligence and decisioning capabilities in Ascend directly into ServiceNow’s workflow, businesses can operate with confidence at scale, while extending the impact of our capabilities into new industries and enterprise workflows. This partnership cements Experian’s position as a global leader in AI innovation, giving organisations the foundations to deploy agentic services with confidence.” Cathy Mauzaize, President, EMEA at ServiceNow, said: “Businesses are ready to move beyond experimentation, and this partnership gives them exactly what they need to scale. By bringing together ServiceNow's AI Platform, with Experian's world-leading decisioning and analytics platform, we're enabling deeper insights and delivering AI that can make smarter decisions and act faster in a secure environment that delivers real outcomes.” The partnership will support a wide range of use cases for companies in highly regulated environments, starting with third-party risk management - including fraud and identity verification for businesses, employee onboarding and model risk management. About Experian Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realise their financial goals and help them to save time and money. We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments. We invest in talented people and new advanced technologies to unlock the power of data and to innovate. A FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 25,200 people across 33 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com. © 2026 ServiceNow, Inc. All rights reserved. ServiceNow, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Other company names, product names, and logos may be trademarks of the respective companies with which they are associated. View source version on businesswire.com: https://www.businesswire.com/news/home/20260514789534/en/ Permalink https://www.aetoswire.com/en/news/1505202655092 Contacts Media contact: Vicki Cook, Head of Corporate and B2B PR, Experian UK&I Tel: +44 7977 798 173 / Email: vicki.cook@experian.com For ServiceNow: press@servicenow.com

Organon to Present New Research on Access and Value at ISPOR 2026

africa-live — Sat, 16 May 2026 05:59:47 GMT

New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio

(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania.

Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas.

“Health economics and outcomes research is critical to ensuring the right treatments reach patients and that health systems can sustain this approach over time,” said Juan Camilo Arjona Ferreira, MD, Head of R&D and Chief Medical Officer at Organon. “At ISPOR 2026, Organon is proud to share research findings about the budget impact, referral patterns, and real-world evidence of treatments for contraception, dermatology, and neurology conditions—each grounded in evidence that puts patient and provider perspectives at the center.”

Key data from Organon’s portfolio to be presented include:

An examination of the cost-effectiveness and budget impact of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque in Brazil, including analyses that incorporate real-world utilization data and private payer perspectives.
A budget impact analysis of VTAMA® (tapinarof) cream, 1%, for the treatment of atopic dermatitis in adult and pediatric patients (2 years of age and older) from a U.S. Medicaid plan perspective.
Analyses related to POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use in certain HER2-positive breast cancer, as well as a real-world budget impact analysis of biosimilar adoption in a mid-sized Brazilian health maintenance organization.
An exploration of real-world referral patterns and healthcare utilization among patients with headache disorders in the United Kingdom, contributing to a better understanding of patient pathways and healthcare resource use in neurology.
Details on the abstracts noted above and additional presentations (including dates and times) can be found below. See below for full product information, including indication and selected safety information.

Date and Time (all times listed in EDT)

Abstract Name

Monday, May 18, 2026 | Poster Session 1 | 10:30 AM-1:30 PM

12:30 PM-1:30 PM: EE71 – Management Based on the Institutionalization of Health Technology Assessment (HTA): The Case of the Etonogestrel Subdermal Implant in a Brazilian Private Health Insurance Plan
12:30 PM-1:30 PM: EE57 – Budget Impact and Cost Calculator Model for POHERDY® (pertuzumab-dpzb) in the Treatment of HER2-Positive Breast Cancer
Monday, May 18, 2026 | Poster Session 2 | 4:00 PM-7:00 PM

6:00 PM-7:00 PM: EE174 – Cost-Effectiveness and Budget Impact of the Etonogestrel Subdermal Contraceptive Implant in Brazil
6:00 PM-7:00 PM: EE100 – Real-World Budget Impact Analysis of Biosimilar Adoption in a Mid-Sized Brazilian Health Maintenance Organization
6:00 PM-7:00 PM: EE172 – Cost-Effectiveness and Budget Impact of the Etonogestrel Subdermal Implant Incorporating Real-World Utilization Data from a Large Brazilian Private Health Insurer
6:00 PM-7:00 PM: HSD27 – Patient Characteristics and Utilization of Adalimumab-bwwd in the U.S. Department of Veterans Affairs Population
Tuesday, May 19, 2026 | Poster Session 4 | 4:00 PM-7:00 PM

6:00 PM-7:00 PM: EE412 – Budget Impact of Introducing Tapinarof, a New Aryl Hydrocarbon Receptor Agonist, for the Treatment of Atopic Dermatitis in Adult and Pediatric Patients from a U.S. Medicaid Plan Perspective
6:00 PM-7:00 PM: SA40 – Real-World Referral Patterns and Healthcare Utilization Among Patients with Headache Disorders in the United Kingdom
About NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

Indication
NEXPLANON® is indicated for prevention of pregnancy in women of reproductive potential for up to 5 years.

Selected Safety Information

WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION and REMOVAL

Improper insertion of NEXPLANON increases the risk of complications.

Proper training prior to first use of NEXPLANON can minimize the risk of improper NEXPLANON insertion.

Because of the risk of complications due to improper insertion and removal NEXPLANON is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the NEXPLANON REMS.

CONTRAINDICATIONS

NEXPLANON should not be used in women who have known or suspected pregnancy; current or past history of thrombosis or thromboembolic disorders; liver tumors, benign or malignant, or active liver disease; undiagnosed abnormal uterine bleeding; known or suspected breast cancer, personal history of breast cancer, or other progestin-sensitive cancer, now or in the past; and/or allergic reaction to any of the components of NEXPLANON.
WARNINGS and PRECAUTIONS
Risk of Complications Due to Improper Insertion and Removal

Complications of Insertion and Removal

NEXPLANON should be inserted subdermally so that it will be palpable after insertion, and this should be confirmed by palpation immediately after insertion. Failure to insert NEXPLANON properly may go unnoticed unless it is palpated immediately after insertion. Undetected failure to insert the implant may lead to an unintended pregnancy. Failure to remove the implant may result in continued effects of etonogestrel, such as compromised fertility, ectopic pregnancy, or persistence or occurrence of a drug-related adverse event.

Complications related to insertion and removal procedures may occur, e.g., pain, paresthesia, bleeding, hematoma, scarring, or infection. If NEXPLANON is inserted deeply (intramuscular or intrafascial), neural or vascular injury may occur.

Postmarketing reports of implants located within the vessels of the arm and the pulmonary artery may have been related to deep insertions or intravascular insertions. Endovascular or surgical procedures may be needed for removal.

Implant removal may be difficult or impossible if the implant is not inserted correctly, is inserted too deeply, not palpable, encased in fibrous tissue, or has migrated. If at any time the implant cannot be palpated, it should be localized, and removal is recommended. When an implant is removed, it is important to remove it in its entirety. Failure to remove the implant may result in continued effects of etonogestrel, such as compromised fertility, ectopic pregnancy, or persistence or occurrence of a drug-related adverse event.
Broken or Bent Implants

Cases of breakage or bending of implants while inserted within a patient’s arm have been reported. Cases of migration of a broken implant fragment within the arm have also occurred. These cases may be related to external forces, e.g., manipulation of the implant or contact sports. The release rate of etonogestrel may be slightly increased in a broken or bent implant, based on in vitro data.
NEXPLANON is available only through a restricted program under a REMS.

NEXPLANON REMS

NEXPLANON is only available through a restricted program under a REMS called NEXPLANON REMS because of the risk of complications due to improper insertion and removal.
Notable requirements of the NEXPLANON REMS include the following:

Healthcare providers must be certified with the program by enrolling and completing training on the proper insertion and removal of NEXPLANON prior to first use.
Pharmacies must be certified with the program and must only dispense NEXPLANON to certified healthcare providers who dispense NEXPLANON for insertion.
Wholesalers and distributors must be registered with the program and must only distribute to certified pharmacies and certified healthcare providers.
Further information is available at www.NEXPLANONREMS.com and 1-833-697-7367.

Changes in Menstrual Bleeding Patterns

After starting NEXPLANON, women are likely to have changes in their menstrual bleeding pattern. These may include changes in frequency, intensity, or duration. Abnormal bleeding should be evaluated as needed to exclude pathologic conditions or pregnancy. In clinical studies of the non-radiopaque etonogestrel implant, reports of changes in bleeding pattern were the most common reason for stopping treatment (11.1%). Women should be counseled regarding bleeding pattern changes that they may experience.
Ectopic Pregnancies

Be alert to the possibility of an ectopic pregnancy in women using NEXPLANON who become pregnant or complain of lower abdominal pain.
Thrombotic and Other Vascular Events

The use of combination hormonal contraceptives increases the risk of vascular events, including arterial events (strokes and myocardial infarctions) or deep venous thrombotic events (venous thromboembolism, deep venous thrombosis, retinal vein thrombosis, and pulmonary embolism). It is recommended that women with risk factors known to increase the risk of venous and arterial thromboembolism be carefully assessed. There have been postmarketing reports of serious arterial thrombotic and venous thromboembolic events, including cases of pulmonary emboli (some fatal), deep vein thrombosis, myocardial infarction, and strokes, in women using etonogestrel implants. NEXPLANON should be removed in the event of a thrombosis. Due to the risk of thromboembolism associated with pregnancy and immediately following delivery, NEXPLANON should not be used prior to 21 days postpartum. Women with a history of thromboembolic disorders should be made aware of the possibility of a recurrence. Consider removal of the NEXPLANON implant in case of long-term immobilization due to surgery or illness.
Ovarian Cysts

If follicular development occurs, atresia of the follicle is sometimes delayed, and the follicle may continue to grow beyond the size it would attain in a normal cycle. Generally, these enlarged follicles disappear spontaneously. Rarely, surgery may be required.
Carcinoma of the Breast and Reproductive Organs

Some studies suggest that the use of combination hormonal contraceptives might increase the incidence of breast cancer and increase the risk of cervical cancer or intraepithelial neoplasia. Women with a family history of breast cancer or who develop breast nodules should be carefully monitored.
Liver Disease

NEXPLANON should be removed if jaundice occurs.
Elevated Blood Pressure

The NEXPLANON implant should be removed if blood pressure rises significantly and becomes uncontrolled.
Gallbladder Disease

Studies suggest a small increased relative risk of developing gallbladder disease among combination hormonal contraceptive users. It is not known whether a similar risk exists with progestin-only methods like NEXPLANON.
Carbohydrate and Lipid Metabolic Effects

Prediabetic and diabetic women using NEXPLANON should be carefully monitored.
Depressed Mood

Women with a history of depressed mood should be carefully observed. Consideration should be given to removing NEXPLANON in patients who become significantly depressed.
Return to Ovulation

In clinical trials with the non-radiopaque etonogestrel implant (IMPLANON), the etonogestrel levels in blood decreased below sensitivity of the assay by one week after removal of the implant. In addition, pregnancies were observed to occur as early as 7 to 14 days after removal. Therefore, a woman should re-start contraception immediately after removal of the implant if continued contraceptive protection is desired.
Fluid Retention

Hormonal contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention. It is unknown if NEXPLANON causes fluid retention.
Contact Lenses

Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.
ADVERSE REACTIONS
Clinical Trial Experience

The most common adverse reaction causing discontinuation of use of the implant in 3-year clinical trials was change in menstrual bleeding patterns (11.1%). The most common adverse reactions (≥5%) reported in these clinical trials were headache (24.9%), vaginitis (14.5%), weight increase (13.7%), acne (13.5%), breast pain (12.8%), abdominal pain (10.9%), and pharyngitis (10.5%). In a separate clinical trial to assess contraceptive efficacy and safety of NEXPLANON beyond 3 years, up to 5 years, a similar adverse reaction profile was observed as in Years 1 through 3. The most frequently reported adverse reaction >5% was intermenstrual bleeding (5.4%). Changes in menstrual bleeding patterns were the most frequently reported adverse reaction leading to discontinuation occurring in 4.0% of participants.
DRUG INTERACTIONS

Effects of Other Drugs on Hormonal Contraceptives

Substances decreasing the plasma concentrations of hormonal contraceptives and potentially diminishing the efficacy of hormonal contraceptives:

Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of hormonal contraceptives and potentially diminish the effectiveness of hormonal contraceptives or increase breakthrough bleeding. Women should use an alternative non-hormonal method of contraception or a back-up method when enzyme inducers are used with hormonal contraceptives, and continue back-up non-hormonal contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability.
Substances increasing the plasma concentrations of hormonal contraceptives:

Co-administration of certain hormonal contraceptives and strong or moderate CYP3A4 inhibitors may increase the serum concentrations of progestins, including etonogestrel.
Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) protease inhibitors and non-nucleoside reverse transcriptase inhibitors:

Significant changes (increase or decrease) in the plasma concentrations of progestin have been noted in cases of co-administration with HIV protease inhibitors, HCV protease inhibitors, or non-nucleoside reverse transcriptase inhibitors. These changes may be clinically relevant.
Effects of Hormonal Contraceptives on Other Drugs

Hormonal contraceptives may affect the metabolism of other drugs. Consequently, plasma concentrations may either increase (for example, cyclosporine) or decrease (for example, lamotrigine).
USE IN SPECIFIC POPULATIONS
Pregnancy

Rule out pregnancy before inserting NEXPLANON.
Lactation

Small amounts of contraceptive steroids and/or metabolites, including etonogestrel are present in human milk. No significant adverse effects have been observed in the production or quality of breast milk, or on the physical and psychomotor development of breastfed infants.
Hormonal contraceptives, including etonogestrel, can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women.
Pediatric Use

The safety and effectiveness of NEXPLANON have been established in women of reproductive potential. Safety and effectiveness of NEXPLANON are expected to be the same in postpubertal adolescents as in adult women. NEXPLANON is not indicated before menarche.
PATIENT COUNSELING INFORMATION

Advise women to contact their healthcare professional immediately if, at any time, they are unable to palpate the implant.

NEXPLANON does not protect against HIV or other STDs.
Before prescribing NEXPLANON, please read the Prescribing Information, including the Boxed Warning. The Patient Information also is available.

About VTAMA® (tapinarof) cream, 1%

INDICATIONS: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor (AhR) agonist indicated for:

the topical treatment of plaque psoriasis in adults
the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older
SELECTED SAFETY INFORMATION

Adverse Events: In plaque psoriasis, the most common adverse reactions (incidence ≥1%) were: folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza.

Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.

Before prescribing VTAMA cream, please read the Prescribing Information.

About POHERDY® (pertuzumab-dpzb)

INDICATIONS AND USAGE

Metastatic Breast Cancer (MBC)
POHERDY is indicated for use in combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Early Breast Cancer (EBC)
POHERDY is indicated for use in combination with trastuzumab and chemotherapy for:

The neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer
The adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence
SELECTED SAFETY INFORMATION

LEFT VENTRICULAR DYSFUNCTION and EMBRYO-FETAL TOXICITY

Pertuzumab products can cause subclinical and clinical cardiac failure manifesting as decreased left ventricular ejection fraction (LVEF) and congestive heart failure (CHF). Evaluate cardiac function prior to and during treatment. Discontinue POHERDY treatment for a confirmed clinically significant decrease in left ventricular function.
Exposure to pertuzumab products can cause embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception.
CONTRAINDICATIONS
POHERDY is contraindicated in patients with known hypersensitivity to pertuzumab products or to any of its excipients.

WARNINGS AND PRECAUTIONS

Left Ventricular Dysfunction
Pertuzumab products can cause left ventricular dysfunction, including symptomatic heart failure. Decreases in LVEF have been reported with drugs that block HER2 activity, including pertuzumab products.

Assess LVEF prior to initiation of POHERDY and at regular intervals during treatment to ensure that LVEF is within normal limits. If the LVEF declines and has not improved, or has declined further at the subsequent assessment, consider permanent discontinuation of POHERDY and trastuzumab.

In the pertuzumab-treated patients with MBC in CLEOPATRA, left ventricular dysfunction occurred in 4% of patients, and symptomatic left ventricular systolic dysfunction (LVSD) (congestive heart failure) occurred in 1% of patients. Patients who received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of decreased LVEF or left ventricular dysfunction.

In patients receiving pertuzumab as a neoadjuvant treatment in combination with trastuzumab and docetaxel in NeoSphere, LVEF decline >10% and a drop to <50% occurred in 8% of patients, and left ventricular dysfunction occurred in 3% of patients. LVEF recovered to ≥50% in all of these patients.

In patients receiving neoadjuvant pertuzumab in TRYPHAENA, LVEF decline >10% and a drop to <50% occurred in 7% of patients treated with pertuzumab plus trastuzumab and fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by pertuzumab plus trastuzumab and docetaxel, 16% of patients treated with pertuzumab plus trastuzumab and docetaxel following FEC, and 11% of patients treated with pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (TCH). Left ventricular dysfunction occurred in 6% of patients treated with pertuzumab plus trastuzumab and FEC followed by pertuzumab plus trastuzumab and docetaxel, 4% of patients treated with pertuzumab plus trastuzumab and docetaxel following FEC, and 3% of patients treated with pertuzumab in combination with TCH. Symptomatic LVSD occurred in 4% of patients treated with pertuzumab plus trastuzumab and docetaxel following FEC, 1% of patients treated with pertuzumab in combination with TCH, and none of the patients treated with pertuzumab plus trastuzumab and FEC followed by pertuzumab plus trastuzumab and docetaxel. LVEF recovered to ≥50% in all but 1 patient.

In patients receiving neoadjuvant pertuzumab in BERENICE, in the neoadjuvant period, LVEF decline ≥10% and a drop to <50% as measured by ECHO/MUGA assessment occurred in 7% of patients treated with pertuzumab plus trastuzumab and paclitaxel following dose-dense doxorubicin and cyclophosphamide (ddAC) and 2% of patients treated with pertuzumab plus trastuzumab and docetaxel following FEC. Ejection fraction decreased (asymptomatic LVD) occurred in 7% of patients treated with pertuzumab plus trastuzumab and paclitaxel following ddAC and 4% of the patients treated with pertuzumab plus trastuzumab and docetaxel following FEC in the neoadjuvant period. Symptomatic LVSD (New York Heart Association [NYHA] Class III/IV Congestive Heart Failure) occurred in 2% of patients treated with pertuzumab plus trastuzumab and paclitaxel following ddAC and none of the patients treated with pertuzumab plus trastuzumab and docetaxel following FEC in the neoadjuvant period.

In patients receiving adjuvant pertuzumab in APHINITY, the incidence of symptomatic heart failure (NYHA Class III/IV) with a LVEF decline ≥10% and a drop to <50% was 0.6%. Of the patients who experienced symptomatic heart failure, 47% of pertuzumab-treated patients had recovered (defined as 2 consecutive LVEF measurements above 50%) at the data cutoff. The majority of the events (86%) were reported in anthracycline-treated patients. Asymptomatic or mildly symptomatic (NYHA Class II) declines in LVEF ≥10% and a drop to <50% were reported in 3% of pertuzumab-treated patients, of whom 80% recovered at the data cutoff.

Pertuzumab products have not been studied in patients with a pretreatment LVEF value of <50%; a prior history of CHF; decreases in LVEF to <50% during prior trastuzumab therapy; or conditions that could impair left ventricular function such as uncontrolled hypertension, recent myocardial infarction, serious cardiac arrhythmia requiring treatment, or a cumulative prior anthracycline exposure to >360 mg/m2 of doxorubicin or its equivalent.

Embryo-Fetal Toxicity
Based on its mechanism of action and findings in animal studies, pertuzumab products can cause fetal harm when administered to a pregnant woman. Pertuzumab products are HER2/neu receptor antagonists. Cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death have been reported with use of another HER2/neu receptor antagonist (trastuzumab) during pregnancy.

Verify the pregnancy status of females of reproductive potential prior to the initiation of POHERDY. Advise pregnant women and females of reproductive potential that exposure to POHERDY in combination with trastuzumab during pregnancy or within 7 months prior to conception can result in fetal harm, including embryo-fetal death or birth defects. Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of POHERDY in combination with trastuzumab.

Infusion-Related Reactions
Pertuzumab products can cause serious infusion reactions, including fatal events.

In CLEOPATRA, on the first day, when only pertuzumab was administered, infusion-related reactions occurred in 13% of patients, and <1% were Grade 3 or 4. The most common infusion reactions (≥1%) were pyrexia, chills, fatigue, headache, asthenia, hypersensitivity, and vomiting. During the second cycle when all drugs were administered on the same day, the most common infusion reactions in the pertuzumab-treated group (≥1%) were fatigue, dysgeusia, hypersensitivity, myalgia, and vomiting.

In APHINITY, when pertuzumab was administered in combination with trastuzumab and chemotherapy on the same day, infusion-related reactions occurred in 21% of patients, with <1% of patients experiencing Grade 3-4 events.

Observe patients closely for 60 minutes after the first infusion and for 30 minutes after subsequent infusions of POHERDY. If a significant infusion-related reaction occurs, slow or interrupt the infusion, and administer appropriate medical therapies. Monitor patients carefully until complete resolution of signs and symptoms. Consider permanent discontinuation in patients with severe infusion reactions.

Hypersensitivity Reactions/Anaphylaxis
Pertuzumab products can cause hypersensitivity reactions, including anaphylaxis.
In CLEOPATRA, the overall frequency of hypersensitivity/anaphylaxis reactions was 11% in pertuzumab-treated patients, with Grade 3-4 hypersensitivity reactions and anaphylaxis occurring in 2% of patients.

In NeoSphere, TRYPHAENA, BERENICE, and APHINITY, hypersensitivity/anaphylaxis events were consistent with those observed in CLEOPATRA. In APHINITY, the overall frequency of hypersensitivity/anaphylaxis was 5% in the pertuzumab-treated group. The incidence was highest in the pertuzumab plus TCH–treated group (8%), with 1% Grade 3-4 events.

Observe patients closely for hypersensitivity reactions. Severe hypersensitivity, including anaphylaxis and fatal events, has been observed in patients treated with pertuzumab products. Angioedema has been described in postmarketing reports. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use prior to administration of POHERDY.

ADVERSE REACTIONS

Metastatic Breast Cancer
The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy.

Neoadjuvant Treatment of Breast Cancer
The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia.

The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of FEC were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia.

The most common adverse reactions (>30%) with pertuzumab in combination with TCH were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia.

The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddAC were nausea, diarrhea, alopecia, fatigue, constipation, peripheral neuropathy, and headache.

The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of FEC were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia.

Adjuvant Treatment of Breast Cancer
The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy, and vomiting.

Before prescribing POHERDY, please read the Prescribing Information, including the Boxed Warning about left ventricular dysfunction and embryo-fetal toxicity.

About HADLIMA® (adalimumab-bwwd) Injection

INDICATIONS AND USAGE

Rheumatoid Arthritis
HADLIMA is indicated, alone or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs), for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.

Juvenile Idiopathic Arthritis
HADLIMA is indicated, alone or in combination with methotrexate, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.

Psoriatic Arthritis
HADLIMA is indicated, alone or in combination with non-biologic DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.

Ankylosing Spondylitis
HADLIMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.

Crohn’s Disease
HADLIMA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.

Ulcerative Colitis
HADLIMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.

Limitations of Use:
The effectiveness of HADLIMA has not been established in patients who have lost response to or were intolerant to tumor necrosis factor (TNF) blockers.

Plaque Psoriasis
HADLIMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HADLIMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Hidradenitis Suppurativa
HADLIMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients.

Uveitis
HADLIMA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.

SELECTED SAFETY INFORMATION

SERIOUS INFECTIONS
Patients treated with adalimumab products, including HADLIMA, are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue HADLIMA if a patient develops a serious infection or sepsis.

Reported infections include:

Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HADLIMA use and during therapy. Initiate treatment for latent TB prior to HADLIMA use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.
Carefully consider the risks and benefits of treatment with HADLIMA prior to initiating therapy in patients:

with chronic or recurrent infection
who have been exposed to TB
with a history of opportunistic infection
who resided in or traveled in regions where mycoses are endemic
with underlying conditions that may predispose them to infection
Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HADLIMA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

Do not start HADLIMA during an active infection, including localized infections.
Patients older than 65 years, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants may be at greater risk of infection.
If an infection develops, monitor carefully and initiate appropriate therapy.
Drug interactions with biologic products: A higher rate of serious infections has been observed in rheumatoid arthritis (RA) patients treated with rituximab who received subsequent treatment with a TNF blocker. An increased risk of serious infections has been seen with the combination of TNF blockers with anakinra or abatacept, with no demonstrated added benefit in patients with RA. Concomitant administration of HADLIMA with other biologic DMARDs (eg, anakinra or abatacept) or other TNF blockers is not recommended based on the possible increased risk for infections and other potential pharmacological interactions.
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including adalimumab products. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants.

Consider the risks and benefits of HADLIMA treatment prior to initiating or continuing therapy in a patient with known malignancy.
In clinical trials, more cases of malignancies were observed among adalimumab-treated subjects compared to control subjects.
Non-melanoma skin cancer (NMSC) was reported during clinical trials for adalimumab-treated subjects. Examine all patients, particularly those with a history of prolonged immunosuppressant or psoralen and ultraviolet A (PUVA) therapy, for the presence of NMSC prior to and during treatment with HADLIMA.
In adalimumab clinical trials, there was an approximate 3-fold higher rate of lymphoma than expected in the general U.S. population. Patients with chronic inflammatory diseases, particularly those with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk of lymphoma than the general population, even in the absence of TNF blockers.
Postmarketing cases of acute and chronic leukemia were reported with TNF blocker use. Approximately half of the postmarketing cases of malignancies in children, adolescents, and young adults receiving TNF blockers were lymphomas; other cases included rare malignancies associated with immunosuppression and malignancies not usually observed in children and adolescents.
HYPERSENSITIVITY
Anaphylaxis and angioneurotic edema have been reported following adalimumab administration. If a serious allergic reaction occurs, stop HADLIMA and institute appropriate therapy.

HEPATITIS B VIRUS REACTIVATION
Use of TNF blockers, including HADLIMA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases have been fatal.

Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating TNF blocker therapy.

Exercise caution in patients who are carriers of HBV and monitor them during and after HADLIMA treatment.

Discontinue HADLIMA and begin antiviral therapy in patients who develop HBV reactivation. Exercise caution when resuming HADLIMA after HBV treatment.

NEUROLOGIC REACTIONS
TNF blockers, including adalimumab products, have been associated with rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, including multiple sclerosis, optic neuritis, and Guillain-Barré syndrome.

Exercise caution when considering HADLIMA for patients with these disorders; discontinuation of HADLIMA should be considered if any of these disorders develop.

HEMATOLOGIC REACTIONS
Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with adalimumab products.

Consider stopping HADLIMA if significant hematologic abnormalities occur.

CONGESTIVE HEART FAILURE
Worsening and new onset congestive heart failure (CHF) has been reported with TNF blockers. Cases of worsening CHF have been observed with adalimumab products; exercise caution and monitor carefully.

AUTOIMMUNITY
Treatment with adalimumab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome or autoimmune hepatitis. Discontinue treatment if symptoms of a lupus-like syndrome or autoimmune hepatitis develop.

IMMUNIZATIONS
Patients on HADLIMA should not receive live vaccines.

Pediatric patients, if possible, should be brought up to date with all immunizations before initiating HADLIMA therapy.

Adalimumab is actively transferred across the placenta during the third trimester of pregnancy and may affect immune response in the in utero-exposed infant. The safety of administering live or live-attenuated vaccines in infants exposed to adalimumab products in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.

ADVERSE REACTIONS
The most common adverse reactions in adalimumab clinical trials (>10%) were: infections (eg, upper respiratory, sinusitis), injection site reactions, headache, and rash.

Before prescribing HADLIMA, please read the Prescribing Information, including the Boxed Warning about serious infections and malignancies. The Medication Guide and Instructions for Use also are available.

About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

Cautionary Note Regarding Forward-Looking Statements
The information above reflects management’s current intentions and expectations for the future with respect to Organon’s expectations regarding milestone expenses, which constitute “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are subject to a number of risks, assumptions, uncertainties and other factors, such as the completion of Organon’s quarter-end closing process, including review by management and the audit committee of the Organon’s board of directors, which could result in material changes to the preliminary estimates described herein. Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the Securities and Exchange Commission ("SEC"), including Organon’s most recent Annual Report on Form 10-K and subsequent SEC filings (as amended, where applicable), available at the SEC’s Internet site (www.sec.gov).

View source version on businesswire.com: https://www.businesswire.com/news/home/20260515139840/en/

Permalink
https://aetoswire.com/en/news/1505202655096

Contacts
Media Contacts:

Janine Colavita
(732) 861-3806

Karissa Peer
(614) 314-8094

Investor Contacts:

Jennifer Halchak
(201) 275-2711

Renee McKnight
(551) 204-6129

The LYCRA Company and Dukane Advance Ultrasonic Bonding for Nonwovens at INDEX™ 26

africa-live — Sat, 16 May 2026 04:57:30 GMT

LYCRA FUSION™ Fiber for Personal Care Applications Debuts

(BUSINESS WIRE)--The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the personal care industry, and Dukane, a manufacturer of ultrasonic bonding technologies for the hygiene and nonwovens market, are showcasing their latest co-developed advances in ultrasonic bonding at INDEX™ 26, taking place in Geneva, Switzerland, from May 19–22.

Since 2014, both companies have collaborated to advance ultrasonic bonding solutions that help diaper manufacturers improve product softness, fit, and performance while reducing energy consumption, material waste, and maintenance costs. Ultrasonic bonding creates bonded channels between two layers of nonwoven materials, mechanically securing elastic fibers without using adhesives. Dukane’s patented rotary and rigid ultrasonic bonding systems enable high-speed, adhesive-free assembly by delivering precisely controlled ultrasonic energy into nonwoven substrates.

LYCRA FUSION™ fiber, originally developed to prevent snags in hosiery from turning into runs, can now fuse to nonwoven layers during ultrasonic bonding. Its sheath/core construction fuses with surrounding materials, strengthens ultrasonic bonds, and delivers superior yarn creep (snapback). When this fiber is paired with Dukane’s advanced ultrasonic bonding modules, manufacturers can achieve precise elastic placement, improved bond integrity, and consistent product performance while eliminating the variability associated with hot-melt adhesives.

“As ultrasonic bonding gains traction in the hygiene industry, our longstanding collaboration with Dukane focuses on expanding technical capabilities while preparing for commercial scale-up,” said Doug Kelliher, executive vice president, product, The LYCRA Company. “We’re excited to introduce LYCRA FUSION™ fiber for personal care, which provides excellent performance with fewer breaking points and improved bond integrity during the ultrasonic bonding process.”

Building on this shared commitment to innovation, The LYCRA Company and Dukane are aligning fiber development with ultrasonic process engineering to support broader adoption of adhesive‑free elastic attachment in nonwovens.

“From ultrasonic lamination to precision sealing and cutting, our technologies are engineered for consistent quality, global scalability, and sustainable production,” said Justin Lafferty, global product development manager - nonwovens, Dukane. “By advancing ultrasonic bonding with LYCRA FUSION™ fiber, we’re helping customers improve product performance while enabling more efficient production.”

Explore more hygiene and nonwovens solutions at The LYCRA Company stand (2151) and the Dukane stand (1568) at INDEX™ 26.

About The LYCRA Company

The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns the leading consumer brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL®. Headquartered in Wilmington, Delaware, U.S., The LYCRA Company is recognized worldwide for its sustainable products, technical expertise, and marketing support. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. Learn more at thelycracompany.com.

About Dukane

Headquartered in St. Charles, DUKANE is a global leader in ultrasonic bonding technologies for the hygiene and personal care industries. Unlike single-approach bonding systems, Dukane offers a range of ultrasonic bonding modules designed to replace adhesive-based processes in hygiene and personal care manufacturing. Manufacturers can select the right bonding technology based on product design, production speed, and long-term operational goals. Dukane’s flexible platform supports intermittent and continuous bonding, as well as blade and rotary technologies, without locking manufacturers into a single technology path. Learn more at dukane.com/nonwoven.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260515514441/en/

Permalink
https://www.aetoswire.com/en/news/54536259

Contacts

Karie J. Ford
Karie.j.ford@lycra.com

Shivani Singh
ssingh@dukane.com

Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio

africa-live — Sat, 16 May 2026 03:44:29 GMT

CONSHOHOCKEN, Pa. - Friday, 15. May 2026 Gong's revenue AI is now natively available in the Boomi Enterprise Platform (BUSINESS WIRE)--Boomi, the data activation company for AI, today announced a collaboration with Gong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security that enterprises require. Through this collaboration, these signals can be served through Boomi Connect as live triggers for AI agents built within Boomi Agentstudio, enabling automated, cross-system workflows, from churn prevention and deal acceleration to post-sale expansion, with centralized oversight. The result is a more connected enterprise, where revenue AI and business operations execute in closer alignment. “The agentic enterprise isn’t built on static data, it’s powered by real-time signals that drive action," said Ed Macosky, Chief Product & Technology Officer at Boomi. "With the depth of Gong’s revenue insights, Boomi provides the foundation to operationalize them within its agent network. Together, we’re helping enterprises close the loop between what customers are saying and how they translate those insights into meaningful, automated action." "The Gong Revenue AI OS orchestrates customer insights across critical revenue workflows, and this integration extends that value across the enterprise," said Eran Aloni, Executive Vice President of Product Strategy and Ecosystem at Gong. "With Boomi, we’re enabling organizations to harness Gong’s AI-driven insights and signals within the Boomi Enterprise Platform to drive coordinated outcomes for customers, seamlessly and at scale." As part of this collaboration: Boomi Connect is designed to provide optimized, governed connectivity to Gong, giving revenue teams access to call data, insights, and rep activity signals with high levels of governance and security. No custom code. Gong will be registered in Boomi’s MCP Registry, making its revenue signals and engagement data accessible to any AI agent on the platform. AI builders get a ready-made, governed data source to act on live Gong signals without building infrastructure from scratch. Boomi is also listed as a native integration on the Gong Collective, giving joint customers a governed, real-time gateway to surface Gong's revenue AI - conversation data, signals, engagement insights, and more - directly inside any MCP-compatible AI tool. A pre-built “Gong recipe” is also now available in the Boomi Marketplace, enabling joint customers to quickly deploy workflows without the need for custom development. Boomi Agentstudio turns signals from Gong into automated actions across the enterprise within its platform. Agents can attach Gong call context to support tickets, route product feedback from customer conversations into roadmap tools, trigger finance workflows tied to deal milestones, and surface competitive intelligence into enablement systems in real time. Boomi’s Agent Control Tower provides centralized visibility and governance over every agent-driven action initiated by Gong signals, ensuring control and accountability at scale. Every action in the Boomi Agent Control Tower is logged, auditable, and bound by enterprise policy, giving security and compliance teams the confidence to scale AI without scaling risk. Boomi World Join the Boomi World keynotes live in Chicago on LinkedIn to hear the latest from Boomi executives, customers, and partners: #BoomiWorld 2026 Live: Day 2 — Thursday, May 14, 9 a.m. Central Learn more about Boomi World Learn more about Boomi World See all of Boomi’s announcements this week in the Boomi Newsroom Follow official event hashtag #BoomiWorld for event coverage on LinkedIn, X, and Instagram About Boomi Boomi, the data activation company for AI, powers the agentic enterprise by bringing data to life across the business. The Boomi Enterprise Platform is the active data foundation that delivers essential agentic infrastructure to drive agentic transformation. By unifying agent design and governance, API and MCP management, integration and automation, and data management into a single platform, Boomi enables organizations to harness the power of AI with secure, scalable connectivity. Trusted by over 30,000 customers and supported by a network of 800+ partners, Boomi helps organizations of all sizes achieve agility, efficiency, and innovation at scale. Discover more at boomi.com. © 2026 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners. View source version on businesswire.com: https://www.businesswire.com/news/home/20260514443012/en/ Permalink https://www.aetoswire.com/en/news/1505202655085 Contacts Media Contact: Kristen Walker Global Communications kristenwalker@boomi.com

Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise

africa-live — Fri, 15 May 2026 17:13:44 GMT

Proposed acquisition extends Boomi’s AI gateway capabilities, enabling enterprises to govern massive volumes of traffic for production-ready AI

(BUSINESS WIRE)--Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems.

As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, security, and performance required for enterprise environments. These capabilities enable organizations to move from pilot to production with confidence, ensuring AI operates reliably, securely, and within defined guardrails.

“At Boomi, we see a clear shift from AI experimentation to real-world deployment,” said Steve Lucas, Chairman and CEO of Boomi. “Our intent to acquire Lunar.dev is focused on one priority: giving customers control over every interaction between AI, data, and applications. That’s essential to building trust and scaling AI with confidence.”

Strengthening AI Governance and Control

With Lunar.dev, Boomi will introduce a centralized and decentralized control layer for managing AI interactions across the enterprise. This enables organizations to:

Enforce fine-grained policy and governance across every AI interaction
Secure and precisely control AI access to enterprise data and systems
Achieve full observability into AI activity, including prompts, responses, and downstream actions
Operate AI at scale with high-performance routing and execution
Deploy with flexibility, including full tenant control across on-premises, private cloud, and sovereign environments
Expanding Boomi Connect with Governed Agent Connectivity

Lunar.dev is expected to become a key component of Boomi Connect, extending Boomi’s ability to enable secure, governed connectivity between AI tools (e.g. Claude, Copilot, Gemini) and enterprise applications through 1000+ managed, MCP-enabled tools. With Lunar.dev, Boomi will add a MCP gateway that additionally provides:

Cost management and observability
Scalable AI connectivity across hybrid and multi-cloud environments
Together with the Boomi MCP Registry, organizations can discover, govern, and manage AI services through a centralized catalog across Boomi and third-party environments.

These capabilities establish Boomi Connect as a unified foundation for governed agent connectivity, enabling organizations to scale AI securely across the enterprise.

Supporting the Next Phase of Agentic AI

This move reflects Boomi’s vision for the agentic enterprise: moving beyond fragmented tools toward a unified platform for connectivity, automation, and governance.

“This is about helping customers turn AI into a trusted, operational capability,” Lucas added. “With governance embedded at every layer, organizations can move faster while staying in control.”

Boomi World

Join the Boomi World keynotes live in Chicago on LinkedIn to hear the latest from Boomi executives, customers, and partners:

#BoomiWorld 2026 Day 1 — Wednesday, May 13, 9 a.m. Central
#BoomiWorld 2026 Live: Day 2 — Thursday, May 14, 9 a.m. Central
Learn more about Boomi World

Learn more about Boomi World
See all of Boomi’s announcements this week in the Boomi Newsroom
Follow official event hashtag #BoomiWorld for event coverage on LinkedIn, X, and Instagram
About Boomi

Boomi, the data activation company for AI, powers the agentic enterprise by bringing data to life across the business. The Boomi Enterprise Platform is the active data foundation that delivers essential agentic infrastructure to drive agentic transformation. By unifying agent design and governance, API and MCP management, integration and automation, and data management into a single platform, Boomi enables organizations to harness the power of AI with secure, scalable connectivity. Trusted by over 30,000 customers and supported by a network of 800+ partners, Boomi helps organizations of all sizes achieve agility, efficiency, and innovation at scale. Discover more at boomi.com.

© 2026 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260513850557/en/

Permalink
https://www.aetoswire.com/en/news/1405202655039

Contacts
Media Contact:
Kristen Walker
Global Communications
kristenwalker@boomi.com

Corona Global Named Most Valuable Beer Brand in Kantar BrandZ Rankings for Third Consecutive Year

africa-live — Fri, 15 May 2026 13:02:27 GMT

LONDON -
AB InBev Holds 8 of the Top 10 Most Valuable Beer Brands Globally

(BUSINESS WIRE)--Corona global has been recognized as the most valuable beer brand in the world for the third consecutive year in Kantar's BrandZ 2026 Most Valuable Global Brands report, released today. Eight out of the top ten most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the best brands in the world.

In 2025, Corona led AB InBev’s performance, increasing revenue by 8.3% outside of its home market with double-digit volume growth in 30 markets, while Corona Cero delivered strong double-digit volume growth. As the brand celebrated its 100th anniversary, Corona launched its global “Corona 100” platform, including a multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro. Strong momentum continued in Q1 2026, with AB InBev delivering all-time high revenues and volume growth, led by Corona, which grew 16% outside its home market following a successful debut as the world’s first global beer sponsor of The Winter Olympics.

In Kantar’s BrandZ 2026 rankings, Corona is followed by Budweiser as the second most valuable beer brand in the world, with Modelo, Michelob ULTRA, Brahma, Bud Light, Skol and Stella Artois helping AB InBev secure 8 of the world’s top 10 most valuable beer brands.

“Corona’s recognition as the most valuable beer brand in the world for three consecutive years reflects our approach to building brands for long-term, sustainable growth,” said Marcel Marcondes, Global Chief Marketing Officer. “For AB InBev to have 8 of the top 10 beer brands in Kantar BrandZ’s 2026 rankings underscores the focus, consistency and creative effectiveness of our teams and partners around the world.”

BrandZ charts the way in which global brands have continued to evolve and innovate. Now in its 21st edition, it spotlights the importance of building meaningful difference where a brand meets consumer needs, stands out from competitors and remains top-of-mind in its sector for a prolonged period.

“Corona’s performance in Kantar BrandZ’s global rankings shows what strong brands achieve when they are built with discipline, over time. Brand value comes from being meaningfully different in ways people recognise, showing up consistently and staying relevant as the world changes. That doesn’t change, even as technology introduces new ways for people to discover and interact with brands. Marketers still need to make clear decisions about what their brand stands for and how it shows up in the real world. That’s something the Corona team continues to get right,” said Paul Zwillenberg, CEO of Kantar.

Kantar BrandZ is a global ranking that assesses brand value by combining financial data and extensive brand equity research, offering an in-depth view of over 22,000 brands in 54 markets.

About AB InBev
Anheuser-Busch InBev (AB InBev) is a publicly traded company (Euronext: ABI) based in Leuven, Belgium, with secondary listings on the Mexico (MEXBOL: ANB) and South Africa (JSE: ANH) stock exchanges and with American Depositary Receipts on the New York Stock Exchange (NYSE: BUD). As a company, we dream big to create a future with more cheers. We are always looking to serve up new ways to meet life’s moments, move our industry forward and make a meaningful impact in the world. We are committed to building great brands that stand the test of time and to brewing the best beers using the finest ingredients. Beer is the drink for moderation, and for over a century, AB InBev has championed responsible drinking. We are committed to providing our consumers with Balanced Choices to enjoy on any occasion. We also invest in marketing that aims to reinforce positive behaviors, and we work with communities, customers, and partners to promote responsible consumption through evidence-based initiatives.

Our diverse portfolio of well over 400 beer brands includes global brands Budweiser®, Corona®, Stella Artois® and Michelob Ultra®; multi-country brands Beck’s®, Hoegaarden® and Leffe®; and local champions such as Aguila®, Antarctica®, Bud Light®, Brahma®, Cass®, Castle®, Castle Lite®, Cristal®, Harbin®, Jupiler®, Modelo Especial®, Quilmes®, Victoria®, Sedrin®, and Skol®. Our brewing heritage dates back more than 600 years, spanning continents and generations. From our European roots at the Den Hoorn brewery in Leuven, Belgium. To the pioneering spirit of the Anheuser & Co brewery in St. Louis, US. To the creation of the Castle Brewery in South Africa during the Johannesburg gold rush. To Bohemia, the first brewery in Brazil. Geographically diversified with a balanced exposure to developed and developing markets, we leverage the collective strengths of approximately 137 000 colleagues based in more than 40 countries worldwide. For 2025, AB InBev’s reported revenue was 59.3 billion USD (excluding JVs and associates).

About Kantar
Kantar is the world’s leading marketing data and analytics business. We deliver the intelligence needed to power brand growth.

We provide the signals that help organisations act quickly and confidently. We empower brands to make effective marketing decisions based on predictive evidence. And we help them craft powerful growth strategies rooted in the connection between consumers, brands and enterprise value. All this is powered by our uniquely robust human and synthetic data, our unrivalled IP, our AI-native platform and the team of global brand experts that bring this all together.

About Kantar BrandZ
Kantar BrandZ is the global currency when assessing brand value, quantifying the contribution of brands to business’ financial performance. Kantar’s annual global and local brand valuation rankings combine rigorously analysed financial data, with extensive brand equity research. Since 1998, BrandZ has shared brand-building insights with business leaders based on interviews with 4.6 million consumers, for over 22,000 brands in 54 markets. Discover more about Kantar BrandZ here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260513211378/en/

Permalink
https://www.aetoswire.com/en/news/1405202655041

Contacts
AB InBev contact
media.relations@ab-inbev.com